Developer docs
API playgroundTry for free, no card

Search company profiles

Clinigen

Full company profile

uuid003yge1

Namestring
Clinigen
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Clinigen is a privately held pharmaceutical services company headquartered in Lismore, Ireland, founded in 2010 with 251–500 employees. Multiple third-party sources describe the company as a provider of pharmaceutical lifecycle services spanning clinical strategy, regulatory navigation, and global commercialization support for enterprise biotech innovators; one firmographic source characterizes it more narrowly as a pharmaceutical manufacturer serving retail pharmacies, hospitals, and wholesalers — a discrepancy that the rest of the corpus (which focuses on biotech-partner services, industry symposia, and commercialization partnerships) does not corroborate. The website (clinigengroup.ie) displays only a default hosting page, so no first-party product material is available.

The company's core offering is an end-to-end engagement model covering clinical strategy through global commercialization, delivered through direct enterprise field sales and amplified via industry symposia at major medical conferences. Its go-to-market targets clinical-stage and commercial-stage biotech innovators that lack internal commercialization infrastructure, including French biotech MaaT Pharma, for which Clinigen supports commercial activities around MaaT013 (acute graft-versus-host disease, currently under EMA review following an MAA submission in June 2025). Distribution is direct to enterprise buyers across global geographies, with the September 2025 acquisition of SSI Strategy adding approximately 200 employees and explicitly extending US and European coverage.

Clinigen earns revenue through professional services and managed-services engagements tied to client commercialization programs and strategic consulting mandates. Pricing is not publicly disclosed. The company operates within the $12–13 billion global pharmaceutical lifecycle services market, which third-party sources estimate will grow at roughly 10% annually through 2030. ESG positioning is part of the corporate profile: in December 2025 the company's greenhouse-gas reduction targets were validated by the Science Based Targets initiative, with a stated net-zero goal by 2040. Ownership structure, leadership beyond a single listed director (Colin Shannon), and revenue figures are not disclosed in the available data.

Short descriptiontext

Clinigen is a privately held Irish pharmaceutical services firm that provides clinical-strategy-to-commercialization support and strategic consulting to enterprise biotech innovators across global markets, including US and European geographies following its 2025 SSI Strategy acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical lifecycle services, biotech commercialization support, clinical strategy consulting, pharmaceutical market access, biotech strategic partnership
Industry3 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
NAICS code2 codes
  • Other Management Consulting Services541618
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Management Consulting Services8742
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Lifecycle Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Lifecycle Services
TypeProfessional Services
Description

Clinigen provides clinical strategy, commercialization support, and strategic consulting services to biotech innovators. The company operates in the $12-13 billion global pharmaceutical lifecycle services market expected to grow at nearly 10% annually through 2030.

pharmiweb.com
2Strategic Commercial Partnership
TypeManaged Services
Description

As strategic commercial partner, Clinigen supports biotech companies with product launches, market access, and commercialization activities including hosting industry symposia and supporting regulatory processes.

pharmiweb.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Clinigen is a pharmaceutical services company that provides end-to-end pharmaceutical lifecycle services, spanning clinical strategy through global commercialization, for biotech innovators. The company operates as a strategic commercial partner, delivering clinical-strategy consulting, commercialization support, regulatory navigation, market access, and product-launch services to biotech and pharmaceutical companies globally. It expanded its capabilities and geographic reach with the September 2025 acquisition of SSI Strategy, a strategic consulting firm for biotech innovators.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Pharmaceutical Lifecycle Services
CategoryPharmaceutical Lifecycle Services
Description

End-to-end clinical-strategy, commercialization, market access, and product-launch support services for biotech innovators globally; covers seamless hand-off from clinical development into commercial stage across multiple regions.

2Strategic Commercial Partnership Services
CategoryPharmaceutical Commercialization
Description

Long-form strategic commercial partnership engagements that combine product-launch support, market access, regulatory navigation, and industry-symposia activation at major medical conferences for clinical-stage biotech companies.

3SSI Strategy Strategic Consulting
CategoryBiotech Strategic Consulting
Description

Strategic consulting services for biotech innovators covering clinical and commercialization support; brought into Clinigen's portfolio via the September 2025 acquisition of SSI Strategy.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Clinigen serves as strategic commercial partner for MaaT Pharma, a French clinical-stage biotechnology company. Clinigen hosts industry symposia and supports commercialization activities for MaaT Pharma's hemato-oncology pipeline, including MaaT013 for acute graft-versus-host disease which is under EMA review following MAA submission in June 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Clinigen acquired SSI Strategy, a strategic consulting firm for biotech innovators. The acquisition added 200 employees and deepened Clinigen's presence in US and European markets, reinforcing its role in the global pharmaceutical lifecycle services market.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO with strong regulatory, clinical, and commercialization capabilities serving biotech and pharma. Comparable as an end-to-end clinical-to-commercial services competitor.

TypeDirect peer
Description

Biopharma solutions organization combining clinical development with commercial/launch services. Closely comparable to Clinigen's 'clinical strategy to commercialization' positioning and biotech-focused customer base.

TypeBroad incumbent
Description

Global CDMO providing development, manufacturing, and commercial services for biologics and small molecules. Comparable as a full-lifecycle services provider to pharma innovators.

TypeDirect peer
Description

Regulatory, compliance, and pharmacovigilance consulting firm serving pharma and biotech. Comparable as a focused medical affairs/regulatory services peer addressing the same late-stage commercialization challenges.

TypeDirect peer
Description

Specialized regulatory affairs, pharmacovigilance, and medical affairs consulting provider for biotech and pharma. Directly comparable to Clinigen's regulatory strategy and medical affairs support offerings.

TypeBroad incumbent
Description

Major global CRO providing clinical research and commercialization services across all phases. Comparable to Clinigen in serving biotech innovators needing end-to-end support from clinical strategy through market launch.

TypeBroad incumbent
Description

Through PPD, offers clinical development and laboratory services to pharma and biotech. Comparable in serving biotech innovators seeking outsourced clinical and commercialization expertise.

TypeBroad incumbent
Description

Global life sciences services giant offering clinical development, real-world evidence, and commercialization/launch services to biotech and pharma. Comparable to Clinigen as a large incumbent competing for the same pharma lifecycle services spend.

TypeBroad incumbent
Description

CDMO and pharma services partner supporting formulation, development, and commercial supply. Comparable to Clinigen's services-and-commercialization model for biotech innovator clients.

TypeBroad incumbent
Description

Provides research models, preclinical/clinical CRO services, and manufacturing support to biotech innovators. Comparable as a life sciences services partner covering drug development lifecycle.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clinigen

Pharmaceutical Lifecycle Servicesclinigengroup.ie

Clinigen is a privately held Irish pharmaceutical services firm that provides clinical-strategy-to-commercialization support and strategic consulting to enterprise biotech innovators across global markets, including US and European geographies following its 2025 SSI Strategy acquisition.

What Clinigen does

Clinigen is a privately held pharmaceutical services company headquartered in Lismore, Ireland, founded in 2010 with 251–500 employees. Multiple third-party sources describe the company as a provider of pharmaceutical lifecycle services spanning clinical strategy, regulatory navigation, and global commercialization support for enterprise biotech innovators; one firmographic source characterizes it more narrowly as a pharmaceutical manufacturer serving retail pharmacies, hospitals, and wholesalers — a discrepancy that the rest of the corpus (which focuses on biotech-partner services, industry symposia, and commercialization partnerships) does not corroborate. The website (clinigengroup.ie) displays only a default hosting page, so no first-party product material is available.

The company's core offering is an end-to-end engagement model covering clinical strategy through global commercialization, delivered through direct enterprise field sales and amplified via industry symposia at major medical conferences. Its go-to-market targets clinical-stage and commercial-stage biotech innovators that lack internal commercialization infrastructure, including French biotech MaaT Pharma, for which Clinigen supports commercial activities around MaaT013 (acute graft-versus-host disease, currently under EMA review following an MAA submission in June 2025). Distribution is direct to enterprise buyers across global geographies, with the September 2025 acquisition of SSI Strategy adding approximately 200 employees and explicitly extending US and European coverage.

Clinigen earns revenue through professional services and managed-services engagements tied to client commercialization programs and strategic consulting mandates. Pricing is not publicly disclosed. The company operates within the $12–13 billion global pharmaceutical lifecycle services market, which third-party sources estimate will grow at roughly 10% annually through 2030. ESG positioning is part of the corporate profile: in December 2025 the company's greenhouse-gas reduction targets were validated by the Science Based Targets initiative, with a stated net-zero goal by 2040. Ownership structure, leadership beyond a single listed director (Colin Shannon), and revenue figures are not disclosed in the available data.

Clinigen firmographics

Firmographics
Name
Clinigen
Website
https://clinigengroup.ie
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Clinigen is a privately held Irish pharmaceutical services firm that provides clinical-strategy-to-commercialization support and strategic consulting to enterprise biotech innovators across global markets, including US and European geographies following its 2025 SSI Strategy acquisition.
Ownership category
akta.pro rank

Clinigen industry classification

Industry
Product category
Pharmaceutical Lifecycle Services
NAICS
Other Management Consulting Services (541618), Scientific Research and Development Services (5417)
SIC
Services-Management Consulting Services (8742), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs

Keywords

  • Pharmaceutical lifecycle services
  • Biotech commercialization support
  • Clinical strategy consulting
  • Pharmaceutical market access
  • Biotech strategic partnership

Where Clinigen is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Clinigen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Pharmaceutical Lifecycle Services: Clinigen provides clinical strategy, commercialization support, and strategic consulting services to biotech innovators. The company operates in the $12-13 billion global pharmaceutical lifecycle services market expected to grow at nearly 10% annually through 2030.
  2. Strategic Commercial Partnership: As strategic commercial partner, Clinigen supports biotech companies with product launches, market access, and commercialization activities including hosting industry symposia and supporting regulatory processes.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Clinigen product offering

Product offering

Core offering

Clinigen is a pharmaceutical services company that provides end-to-end pharmaceutical lifecycle services, spanning clinical strategy through global commercialization, for biotech innovators. The company operates as a strategic commercial partner, delivering clinical-strategy consulting, commercialization support, regulatory navigation, market access, and product-launch services to biotech and pharmaceutical companies globally. It expanded its capabilities and geographic reach with the September 2025 acquisition of SSI Strategy, a strategic consulting firm for biotech innovators.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Lifecycle Services End-to-end clinical-strategy, commercialization, market access, and product-launch support services for biotech innovators globally; covers seamless hand-off from clinical development into commercial stage across multiple regions.
  • Strategic Commercial Partnership Services Long-form strategic commercial partnership engagements that combine product-launch support, market access, regulatory navigation, and industry-symposia activation at major medical conferences for clinical-stage biotech companies.
  • SSI Strategy Strategic Consulting Strategic consulting services for biotech innovators covering clinical and commercialization support; brought into Clinigen's portfolio via the September 2025 acquisition of SSI Strategy.

Companies that use Clinigen

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Clinigen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Clinigen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MaaT PharmacoreStrategic or Co-development Partner · 9 March 2026Clinigen serves as strategic commercial partner for MaaT Pharma, a French clinical-stage biotechnology company. Clinigen hosts industry symposia and supports commercialization activities for MaaT Pharma's hemato-oncology pipeline, including MaaT013 for acute graft-versus-host disease which is under EMA review following MAA submission in June 2025.
  • SSI StrategycoreStrategic or Co-development Partner · 29 September 2025Clinigen acquired SSI Strategy, a strategic consulting firm for biotech innovators. The acquisition added 200 employees and deepened Clinigen's presence in US and European markets, reinforcing its role in the global pharmaceutical lifecycle services market.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Clinigen competitors and assessment

Company assessment

Broad incumbents

  • Parexel International: Global CRO with strong regulatory, clinical, and commercialization capabilities serving biotech and pharma. Comparable as an end-to-end clinical-to-commercial services competitor.
  • Lonza Group: Global CDMO providing development, manufacturing, and commercial services for biologics and small molecules. Comparable as a full-lifecycle services provider to pharma innovators.
  • ICON plc: Major global CRO providing clinical research and commercialization services across all phases. Comparable to Clinigen in serving biotech innovators needing end-to-end support from clinical strategy through market launch.
  • Thermo Fisher Scientific (PPD): Through PPD, offers clinical development and laboratory services to pharma and biotech. Comparable in serving biotech innovators seeking outsourced clinical and commercialization expertise.
  • IQVIA: Global life sciences services giant offering clinical development, real-world evidence, and commercialization/launch services to biotech and pharma. Comparable to Clinigen as a large incumbent competing for the same pharma lifecycle services spend.
  • Catalent: CDMO and pharma services partner supporting formulation, development, and commercial supply. Comparable to Clinigen's services-and-commercialization model for biotech innovator clients.
  • Charles River Laboratories: Provides research models, preclinical/clinical CRO services, and manufacturing support to biotech innovators. Comparable as a life sciences services partner covering drug development lifecycle.

Direct peers

  • Syneos Health: Biopharma solutions organization combining clinical development with commercial/launch services. Closely comparable to Clinigen's 'clinical strategy to commercialization' positioning and biotech-focused customer base.
  • ProPharma Group: Regulatory, compliance, and pharmacovigilance consulting firm serving pharma and biotech. Comparable as a focused medical affairs/regulatory services peer addressing the same late-stage commercialization challenges.
  • PharmaLex (now part of Cencora): Specialized regulatory affairs, pharmacovigilance, and medical affairs consulting provider for biotech and pharma. Directly comparable to Clinigen's regulatory strategy and medical affairs support offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Clinigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clinigen leadership team

Management profile

Number of profiles

Profiles1 record

Clinigen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clinigen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinigen

What does Clinigen do?

Clinigen is a pharmaceutical services company that provides end-to-end pharmaceutical lifecycle services, spanning clinical strategy through global commercialization, for biotech innovators. The company operates as a strategic commercial partner, delivering clinical-strategy consulting, commercialization support, regulatory navigation, market access, and product-launch services to biotech and pharmaceutical companies globally. It expanded its capabilities and geographic reach with the September 2025 acquisition of SSI Strategy, a strategic consulting firm for biotech innovators.

When was Clinigen founded?

Clinigen was founded in 2010. It employs 501 to 1,000 people.

Where is Clinigen based?

Clinigen is headquartered in London, United Kingdom, in the Europe region.

How does Clinigen make money?

Two revenue lines are on record. Pharmaceutical Lifecycle Services are the primary driver. The others are strategic Commercial Partnership.

Who are Clinigen's main competitors?

Broad incumbents on record are Parexel International, Lonza Group, ICON plc, Thermo Fisher Scientific (PPD), IQVIA, Catalent and Charles River Laboratories. Direct peers are Syneos Health, ProPharma Group and PharmaLex (now part of Cencora).

Does Clinigen have an API?

No public API is recorded for Clinigen.

What industry is Clinigen in?

Clinigen's product category is Pharmaceutical Lifecycle Services. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs. Its NAICS code is 541618 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarClinigen Appoints Greg Skalicky as Chief Executive OfficerClinigen appointed Greg Skalicky as Group CEO, effective 20 July 2026, succeeding Dr Varun Sethi as Acting CEO. Skalicky brings over 30 years of experience, including as President of Eversana. He will lead Clinigen's next growth phase, serving over 1,000 pharmaceutical and biotechnology partners globally.BioSpaceMaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026MaaT Pharma reported Q1 2026 revenues of €0.8 million and cash of €18.1 million as of March 31, 2026. The company received a negative trend opinion on its MaaT013 (Xervyteg) marketing authorization application from the EMA, with a re-examination planned. Cash runway extends to November 2026.BioSpaceMaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD ManagementMaaT Pharma will present final results from its ARES pivotal Phase 3 trial evaluating MaaT013 in acute Graft-versus-Host Disease at the 2026 EBMT Annual Meeting in Madrid, March 22–25, 2026. The company will also present three poster communications covering CHRONOS, PHOEBUS, and THRASSA studies, while strategic partner Clinigen will host a related industry symposium on steroid-refractory aGvHD management. MaaT013 is currently under EMA review following a Marketing Authorization Application submission in June 2025.PharmiWeb.comMaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD ManagementMaaT Pharma, a French clinical-stage biotechnology company, will present clinical data from its hemato-oncology pipeline at the 2026 EBMT Annual Meeting in Madrid (March 22-25, 2026), including final results from the ARES pivotal Phase 3 trial for MaaT013 in acute graft-versus-host disease. The company's lead asset MaaT013 is currently under review by the European Medicines Agency following a Marketing Authorization Application submission in June 2025. Additionally, Clinigen, MaaT Pharma's strategic commercial partner, will host an industry symposium on steroid-refractory gastrointestinal aGvHD management.BioWorldIovance ‘leukin good after Clinigen transaction as lifileucel BLA stays the courseIovance acquired worldwide rights to Clinigen's Proleukin (aldesleukin) for £166.7 million upfront and a £41.7 million milestone upon lifileucel's first approval in advanced melanoma. The deal includes double-digit global royalties for Clinigen.